X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funds will enable Amarna to advance its lead gene therapy AMA005, for the treatment of hemophilia B towards a first-in-human clinical trial, and to progress its R&D pipeline in selected autoimmune diseases and chronic inflammation.
Lead Product(s): AMA005
Therapeutic Area: Genetic Disease Product Name: AMA005
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: C4 holding BV
Deal Size: $5.7 million Upfront Cash: Undisclosed
Deal Type: Financing December 01, 2021
Details:
The collaboration is a joint effort between the research group of the FPS at research institute Cabime and Amarna Therapeutics which aims to assess the efficacy of SVec in reducing the immune responses that trigger the damage and loss of myelin in animal models of MS.
Lead Product(s): SV40 vector based gene therapy
Therapeutic Area: Neurology Product Name: SVec
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Progreso y Salud Foundation
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
